Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Agnes H. Chan"'
Autor:
David W. C. Hunt, Agnes H. Chan
Publikováno v:
Expert Opinion on Investigational Drugs. 9:807-817
Photodynamic therapy (PDT) utilises light-absorbing compounds combined with directed photo-irradiation to produce clinical effects. This review updates advances in the understanding of the biochemical pathways triggered by PDT within cells, its influ
Autor:
Agnes H. Chan, David J. Granville, Huijun Jiang, Simon Leong, Julia G. Levy, David W. C. Hunt
Publikováno v:
Immunopharmacology. 41:31-44
The impact of the immunomodulatory photosensitizer benzoporphyrin derivative monoacid ring A (BPD-MA, verteporfin) and visible light on the survival and surface receptor pattern of resting and activated murine T cells was evaluated. T cells treated f
Publikováno v:
Photochemistry and Photobiology. 64:751-757
Transcutaneous photodynamic therapy (PDT), utilizing benzoporphyrin derivative monoacid ring A (BPD, verteporfin) and whole-body light exposure, was assessed for its capacity to modify the course of adoptively transferred experimental autoimmune ence
Publikováno v:
Photochemistry and Photobiology. 61:417-421
— This study compared the ability of highly purified resting and activated DBA/2 mouse peritoneal macrophages to survive treatment with the photosensitizer benzoporphyrin derivative (BPD, verteporfin) and light. Culture of macrophages with recombin
Autor:
Julia G. Levy, Agnes H. Chan, Harvey Lui, David W. C. Hunt, John Robert North, Guillermo O. Simkin, Leslie G. Ratkay
Publikováno v:
SPIE Proceedings.
Photodynamic Therapy (PDT) is accepted for treatment of superficial and lumen-occluding tumors in regions accessible to activating light and is now known to be effective in closure of choroidal neovasculature in Age Related Macular Degeneration. PDT
Publikováno v:
Immunopharmacology. 37(2-3)
Four structural analogs of benzoporphyrin derivative (BPD), a potent anti-tumor photosensitizer, were evaluated for their capacity to influence the immunologically-mediated contact hypersensitivity (CHS) response against the hapten 2,4-dinitrofluorob
Publikováno v:
SPIE Proceedings.
Benzoporphyrin derivative monoacid ring A (BPD) is currently in Phase II clinical trials for the treatment of cutaneous malignancies (basal cell carcinoma and cutaneous metastases) and psoriasis. Results to date suggest that this photosensitizer has
Publikováno v:
SPIE Proceedings.
In this study, the effect of transdermal photodynamic therapy (PDT) using benzoporphyrin derivative monoacid ring A (BPD) on the development of the immunologically mediated contact hypersensitivity (CHS) response against the hapten dinitrofluorobenze
Autor:
Modestus Obochi, Agnes H. Chan, Douglas Waterfield, Leslie G. Ratkay, David W. C. Hunt, R. K. Chowdhary, Simon Leong, Julia G. Levy
Publikováno v:
Proceedings of SPIE.
The photosensitizer benzoporphyrin derivative monoacid ring A (VerteporfinR or BPD) has maximum absorption characteristics (690 nm) and biodistribution characteristics which permit activation of the drug in capillaries of the skin without causing ski
Publikováno v:
SPIE Proceedings.
Photodynamic therapy (PDT) using benzoporphyrin derivative (BPD, Verteporfin) and whole body irradiation, can affect the course of adoptively transferred experimental allergic (autoimmune) encephalomyelitis (EAE) in PL mice. Murine EAE is a T cell-me